Dublin, Nov. 06, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/qtwr6t/nextgeneration) has announced the addition of the "Next-Generation Glycemic Control Therapeutics" report to their offering.

As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development.

New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.

Highlights

- What therapeutic drugs are currently marketed for glycemic control, how are they administered, who markets them, and what is the size of the global market?
- What are the important factors in patient self-administration of glycemic drugs, what are the current prescribing trends, and what are the key factors influencing demand?
- What are the regional factors affecting market size and demand?
- What are the new classes of drugs that are entering the market for treating diabetes, what is their market share and what are their growth prospects?
- What drugs are expected to enter the market in the next five years, and what will be their probable impact on the overall market?
- What are the significant economic, technology, and regulatory factors affecting the market for glycemic control therapeutics?

Key Topics Covered:

1. Executive Summary

2. The Market Opportunity
- Glycemic Control Market Dynamics
- Market Segments
- What's Driving the Market?
- Shifting Demographics
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors

3. Approved Next-Generation Therapeutics
- Inhaled Insulin
- GLP-1 Agonists
- Amylin Analogs
- DPP-4 Inhibitors
- Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors

4. Development-stage Glycemic Control Products
- Insulins
- Inhaled Insulin
- GLP-1 Agonists
- DPP-4 Inhibitors
- SGLT2 Inhibitors
- Dual Therapy Drugs
- New MOAs
- PPARs
- Glucagon Receptor Antagonist

5. Market Data and Forecasts

6. Market Factors
- Regulatory Issues
- Patient Compliance and Ease of Use
- Healthcare Economics
- Regional Market Factors

7. Company Profiles

For more information visit http://www.researchandmarkets.com/research/qtwr6t/nextgeneration

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Pharmaceuticals

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.